Aurora Cannabis Inc
NASDAQ: ACB · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-05-08
Aurora Cannabis Inc (ACB) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for ACB.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
ACB historical valuation range
Where current P/E sits in ACB's own 5Y range.
ACB intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Standard discounted cash flow models produce unreliable output for unprofitable or near-breakeven companies. Revenue-based multiples such as P/S and EV/Sales, combined with the historical valuation position above, give a more reliable read for this stock.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
ACB valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 0.54x
Is ACB overvalued in 2026?
Aurora Cannabis Inc (ACB) currently trades at $3.41 per share with a market capitalization of $202,804,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 34/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
ACB currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 0.5x, the market is valuing the company primarily on its revenue rather than its earnings.
A standard DCF model does not produce reliable output for ACB under current conditions. For unprofitable or near-breakeven companies, revenue-based multiples such as EV/Sales and historical P/S percentile are more informative than intrinsic value calculations.
The Piotroski F-Score of 5/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: ACB appears richly valued on our framework, with a Smart Value Score of 34/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is ACB overvalued in 2026?
Based on a Smart Value Score of 34/100, ACB appears overvalued. Current price exceeds what fundamentals currently justify.
What is ACB's fair value?
Standard DCF is unreliable for ACB due to its current profitability profile. Revenue-based approaches such as EV/Sales or historical P/S percentile are more informative for this stock.
What P/E ratio does ACB trade at?
ACB does not have a meaningful P/E ratio at this time, typically a sign of unprofitability or an ongoing earnings transition.
Is ACB a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 34/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does ACB's valuation compare to its history?
Insufficient historical valuation data exists yet for a confident percentile read on ACB.
What is ACB's Smart Value Score?
ACB's Smart Value Score is 34/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.